Virtual Library
Start Your Search
Z. Elsayed
Author of
-
+
P2.07 - Poster Session/ Small Cell Lung Cancer (ID 222)
- Event: WCLC 2015
- Type: Poster
- Track: Small Cell Lung Cancer
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.07-012 - Accelerated Hypofractionated Radiotherapy and Concurrent Etoposide / Cisplatin in Patients with Limited-Disease SCLC (LD-SCLC) (ID 1244)
09:30 - 09:30 | Author(s): Z. Elsayed
- Abstract
Background:
The optimal TRT dose/fraction for LS-SCLC remains debatable, and due to increasing number of population in Egypt and number of patients as well, so reducing the duration of radiation therapy is favored. This study was conducted using etoposide and cisplatin (EP) concurrently with accelerated hypofractionated thoracic radiation therapy to evaluate the response and toxicity of this protocol in the treatment of patients with limited-disease small cell lung cancer (LD-SCLC).
Methods:
Thirty patients with previously untreated LD-SCLC were enrolled into this study between June 2012 and February 2015. All patients received etoposide 100 mg/m[2 ]days 1 to 3 and cisplatin 25 mg/m[2 ]days 1 to 3 with start of accelerated hypofractionated thoracic radiation therapy on first day of the second cycle of chemotherapy of 55 Gy,2.5 Gy/ fraction over 30 days. Chemotherapy was given 4-6 cycles. Prophylactic cranial irradiation 25 Gy in 10 daily fractions was given for patient who achieved complete remission.
Results:
The median age was 61 years; 28 patients (93%) were men. ECOG PS was 0 in 6 (20%) patients , 1 in 20 (67%) patients and 2 in 4(13%) patients. Five (17%) patients achieved a complete response (CR), 22 (73%) patients achieved a partial response (PR), while 2 patients (7%) had progressive disease (PD) and 1(3 %) patients achieved stable disease; therefore, the overall response rate was 90%. The median survival time was 26.4 months and 1- and 2-year survival rates were 78% and 58.3%, respectively. The median progression-free survival (PFS) was 16.7 months, and 1- and 2-year PFS times were 60% and 41.4%, respectively. Among the hematologic toxicities neutropenia was the most prevalent toxicity and it was evident as grade 3-4 in 12 patients (40%). Grade 3-4 Asthenia was the most prevalent nonhematological toxicity, in 12 patients (40%); esophagitis occurred in 7 patients (23%). No treatment-related deaths (due to sepsis or bleeding) were reported in the study.
Conclusion:
Using etoposide and cisplatin concurrently with accelerated hypofractionated thoracic radiation therapy for the treatment of patients with LD-SCLC showed an encouraging outcomes and acceptable toxicity and warrants further research.
